Japanese encephalitis (JE) is primarily transmitted through the bite of infected mosquitoes, predominantly species of the Culex genus, with Culex tritaeniorhynchus being a common vector. The virus circulates in an enzootic cycle involving mosquitoes and vertebrate hosts, particularly pigs and wading birds. Humans are incidental hosts and can become infected when bitten by an infected mosquito. The transmission risk is higher in rural and agricultural areas, where there is closer proximity to the natural habitats of mosquitoes and their reservoir hosts. Human-to-human transmission is rare, with no evidence of direct person-to-person spread.

The diagnosis of Japanese encephalitis (JE) involves a combination of clinical evaluation, laboratory tests, and imaging studies. Initial symptoms may be non-specific, resembling other viral infections, making it challenging to diagnose based solely on clinical presentation. Blood tests, such as reverse transcription-polymerase chain reaction (RT-PCR) or enzyme-linked immunosorbent assay (ELISA), can be employed to detect the presence of the Japanese encephalitis virus (JEV) or specific antibodies in the blood or cerebrospinal fluid. Additionally, imaging studies, such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, may reveal characteristic changes in the brain indicative of encephalitis.

Preventing Japanese encephalitis (JE) involves a comprehensive approach focusing on vaccination, mosquito control, and public health measures. Vaccination is a key preventive strategy, and various vaccines are available for at-risk populations, particularly those residing in or traveling to endemic regions. Mosquito control measures, such as the use of insecticides, bed nets, and environmental management to reduce mosquito breeding sites, play a crucial role in minimizing the risk of transmission. Public health education and awareness campaigns help inform communities about preventive measures, the importance of vaccination, and steps to avoid mosquito bites.

There is no specific antiviral treatment for Japanese encephalitis (JE), and management primarily focuses on supportive care to alleviate symptoms and reduce complications. Hospitalization is often necessary for individuals with severe cases, especially those displaying neurological symptoms. Supportive measures include intravenous fluids, antipyretics to control fever, and medications to manage seizures. In critical cases, mechanical ventilation may be required. While there is no cure for JE, prevention through vaccination is a crucial aspect of controlling the disease, particularly in endemic regions.